



ASX ANNOUNCEMENT

Lumos to present at NWR Virtual Healthcare Conference

MELBOURNE, Australia (17 March 2023) – Lumos Diagnostics (ASX: LDX), (“Lumos” or the “Company”) is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

CEO Doug Ward will present at 10:20am AEDT on Wednesday 22 March 2023.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: https://us02web.zoom.us/webinar/register/WN_C4H4zPrjRHqqmqlgtglAEw

A recording will be available at the above link shortly after the conclusion of the live session.

Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au

For more information please visit: <https://nwrcommunications.com/healthconf>

This announcement has been approved by the Lumos Disclosure Committee.

-Ends-

About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com or febridx.com.

Media Contact:

Matthew Wright – Australia
Director, NWR Communications
matt@nwrcommunications.com.au
+61 (0) 451 896 420

Investor Contact:

Matthijs Smith – Lumos Diagnostics
ir@lumosdiagnostics.com
+61 3 9087 1598

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Level 4, 100 Albert Rd
South Melbourne, VIC 3205
+61 3 9087 1598